Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for Targeted RAS Pathway Inhibitors in Advanced Solid Tumors

Targeted inhibitors of the RAS signaling pathway have moved from a historically undruggable target class to a growing portfolio of clinically active agents in advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancer. This article is written from the perspective of a clinical trial manager responsible for carrying a RAS pathway inhibitor program from its initial Investigational New Drug (IND) application or Clinical Trial Application (CTA) through the protocol amendments that inevitably follow as early clinical data accumulate. It reviews the mechanistic rationale for this drug class, the rationale for trial phase, setting, and population selection, best practices for first-in-human and dose-expansion protocol design, anticipated risks and pharmacovigilance monitoring strategy, statistical sample-size rationale drawn from registered trials, the detailed regulatory requirements, templates, and timelines governing both the initial IND or CTA submission and subsequent amendments under FDA, Health Canada, and EMA frameworks, a representative schedule of assessments spanning a twelve-month treatment period, and the application of artificial intelligence tools to data capture and data quality. The article closes with recommendations for regulatory affairs and clinical operations professionals managing this therapeutic category.Keywords: RAS pathway inhibitors; KRAS; protocol amendment; Investigational New Drug application; Clinical Trial Application; pharmacovigilance; sample size; regulatory artificial intelligence